AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 82 min read$ANGO

ANGIODYNAMICS INC (ANGO): Entry into a Material Definitive Agreement

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 NEWS RELEASE Investor Contact: Stephen Trowbridge Executive Vice President & CFO 518-795-1408 strowbridge@angiodynamics.com Media Contact: Saleem Cheeks Vice President, Communications 518-795-1174 scheeks@angiodynamics.com AngioDynamics Announces Appointment of Eric

Original reporting
SEC EDGAR 8-K
Published Oct 8, 2026, 11:16 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ANGO
Neutral
medium confidence
Mentioned
$ANGO
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

The appointment of a seasoned executive from major med‑tech firms may be viewed as a positive catalyst for future growth, though immediate price reaction is likely muted.

02

Market read

Executive change is a material corporate event for AngioDynamics (ANGO) and may influence its valuation over the coming quarters.

03

What to watch

Potential hidden cost synergies or cultural integration issues not disclosed.

Relevance 6/10Novelty 7/10Timing: effective November 2, 2026

Background

AngioDynamics filed an 8‑K reporting a material definitive agreement and a change in senior management.

Company-level read

Ticker impact

$ANGONeutralMedium confidence
Context

SEC Form 8‑K announces Eric Honroth will become President and CEO effective Nov 2 2026, replacing Jim Clemmer.

Expected impact

potential modest upside as investors price in new CEO experience

Evidence & confidence

A new CEO with a strong medical‑device background could improve growth outlook, but impact is uncertain and likely gradual.

Market effects

Sector

May signal continued focus on vascular and oncology device markets, potentially benefiting peers.

Regional

Limited to U.S. med‑tech sector; no broader regional effect.

Global

Low global relevance beyond medical‑technology investors.

Counterpoint

What could challenge this read

New leadership could disrupt existing momentum if integration challenges arise.

Key entities

  • person
    Eric Honroth

    Incoming President and CEO of AngioDynamics

  • person
    Jim Clemmer

    Outgoing President and CEO, transitioning to advisory role

Read at source← All news

Related articles

OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com2 min
OCT 14
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com2 min
OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com2 min
OCT 9
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com5 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com3 min